Eating fresh grapes provides the same heart-health benefits touted
for red wine, finds new research published this month by a group of
researchers from the University of Connecticut. The team found that
table grapes from California...
Dutch food and nutrition group Numico is to sell its
underperforming US vitamin unit Rexall Sundown in a bid to boost
profits, the company said today. The world's biggest vitamin and
supplement maker reported a 32 per cent drop...
A Mediterranean-style diet could help reduce cardiovascular disease
in Asian populations, especially among Asian people living in
western countries, according to a study by researchers from India
and Israel published in The Lancet...
Leading German chemical company BASF said today its third quarter
earnings will be impacted by a €100 million charge resulting from
the final settlements with purchasers of its vitamin products in
A team of US and UK-based scientists presented research about an
appetite-reducing hormone found naturally in the body this week.
The findings are seen as an important step towards creating an
Yesterday we reported on a major study to investigate a potential
cancer drug based on red wine compounds. However there is also
evidence to show that wine can have harmful effects. Researchers in
France report that heavy wine drinkers...
A Hebrew University parasitologist claims to have shown that a
natural head lice remedy is more effective than the commonly-used
conventional medication. The study is published in the October
issue of the Journal of the Israel Medical...
British healthcare retailer and chemist Boots today reported a drop
in interim profits by almost 3 per cent to £279.6 million (€m) for
the first six months ended 30 September 2002. Profits were impacted
by a £40m investment in Boots...
Cannabis-based medicine could be on the UK market as early as 2003,
according to GW Pharmaceuticals, the UK company developing
cannabis-based prescription medicines, which this week released
results from four Phase III clinical trials.
Evolutec, the British biotechnology company which develops novel
therapeutic products from parasites, is to begin Phase I and II
clinical trials with rEV131, its treatment for allergic and